We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
- Authors
Chang, J; Varghese, D S; Gillam, M C; Peyton, M; Modi, B; Schiltz, R L; Girard, L; Martinez, E D
- Abstract
Over the last decade, several drugs that inhibit class I and/or class II histone deacetylases (HDACs) have been identified, including trichostatin A, the cyclic depsipeptide FR901228 and the antibiotic apicidin. These compounds have had immediate application in cancer research because of their ability to reactivate aberrantly silenced tumour suppressor genes and/or block tumour cell growth. Although a number of HDAC inhibitors are being evaluated in preclinical cancer models and in clinical trials, little is known about the differences in their specific mechanism of action and about the unique determinants of cancer cell sensitivity to each of these inhibitors.
- Publication
British journal of cancer, 2012, Vol 106, Issue 1, p116
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2011.532